Evidence map›Paper›PMID 26407622›Full record

Observational studyEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2015

COPD patients with ventilator-associated pneumonia: implications for management.

D Koulenti, S Blot, J M Dulhunty, L Papazian, I Martin-Loeches, G Dimopoulos, C Brun-Buisson, M Nauwynck, C Putensen, J Sole-Violan and 3 more

Open access · bronzeAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Guideline
  2. Observational
  3. Article
  4. Article
  5. Protocol for an international, multicentre, prospective, observational study of nosocomial pneumonia in intensive care units: the PneumoINSPIRE study.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2021
    Article
  6. Article
  7. Article
  8. Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2020
    Article
  9. Review
  10. Article
  11. Article
  12. The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence?European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019
    Review
  13. Article
  14. Article
  15. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017
    Review
  16. Article
  17. Article
  18. Ventilator-associated pneumonia in patients on prolonged mechanical ventilation: description, risk factors for mortality, and performance of the SOFA score.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 7 countries.

D Koulenti2nd Critical Care Department, Attikon University Hospital, Athens, Greece.
S BlotBurns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia. stijn.blot@UGent.be.
J M DulhuntyBurns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia.
L PapazianDepartment of Intensive Care Medicine, Réanimation des Détresses Respiratoires et Infections Sévères Hôpital Nord-Assistance Publique-Hôpitaux de Marseille Aix-Marseille Université, Μarseille, France.
I Martin-LoechesDepartment of Intensive Care Medicine, Corporació Sanitària Parc Taulí, Sabadell, Spain.
G Dimopoulos2nd Critical Care Department, Attikon University Hospital, Athens, Greece.
C Brun-BuissonDepartment of Intensive Care Medicine, Henri-Mondor University Hospital, Paris, France.
M NauwynckDepartment of Intensive Care Medicine, St. Jan Hospital, Bruges, Belgium.
C PutensenDepartment of Intensive Care Medicine, Bonn University Hospital, Bonn, Germany.
J Sole-ViolanDepartment of Intensive Care Medicine, Dr. Negrin University Hospital, Las Palmas, Gran Canaria, Spain.
A Armaganidis2nd Critical Care Department, Attikon University Hospital, Athens, Greece.
J RelloCritical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
EU-VAP/CAP Study Group
The University of Queensland · AUUniversitat Autònoma de Barcelona · ESUniversity Hospital Bonn · DEAix-Marseille Université · FRAZ Sint-Jan · BEHôpitaux Universitaires Henri-Mondor · FRHospital Universitario de Gran Canaria Doctor Negrín · ESMater Misericordiae University Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on the occurrence and outcome of patients with chronic obstructive pulmonary disease (COPD) and ventilator-associated pneumonia (VAP) are quite limited. The aim of this study was to determine if COPD intensive care unit (ICU) patients have a higher rate of VAP development, different microbiological aetiology or have worse outcomes than other patients without VAP. A secondary analysis of a large prospective, observational study conducted in 27 European ICUs was carried out. Trauma patients were excluded. Of 2082 intubated patients included in the study, 397 (19.1%) had COPD; 79 (19.9%) patients with COPD and 332 (19.7%) patients without COPD developed VAP. ICU mortality increased by 17% (p < 0.05) when COPD patients developed VAP, remaining an independent predictor of mortality [odds ratio (OR) 2.28; 95% confidence interval (CI) 1.35-3.87]. The development of VAP in COPD patients was associated with a median increase of 12 days in the duration of mechanical ventilation and >13 days in ICU stay (p < 0.05). Pseudomonas aeruginosa was more common in VAP when COPD was present (29.1% vs. 18.7%, p = 0.04) and was the most frequent isolate in COPD patients with early-onset VAP, with a frequency 2.5 times higher than in patients without early-onset VAP (33.3% vs. 13.3%, p = 0.03). COPD patients are not more predisposed to VAP than other ICU patients, but if COPD patients develop VAP, they have a worse outcome. Antibiotic coverage for non-fermenters needs to be included in the empiric therapy of all COPD patients, even in early-onset VAP.

Indexed as

AdultAgedAged, 80 and overAnti-Bacterial AgentsEuropeFemaleHumansIntensive Care UnitsMaleMiddle AgedPneumonia, Ventilator-AssociatedProspective StudiesPseudomonas aeruginosaPulmonary Disease, Chronic ObstructiveSurvival AnalysisTreatment OutcomeAnti-Bacterial Agents

Identifiers

PMID26407622
OpenAlexW2101989805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.